Godište 35 supplement 2 - Institut za reumatologiju

9. Van den Hoogen FH, et al. Comparison of methotrexate with placebo in the treatment of systemic
sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observation trial. Br J
Rheumatol 1996;35:364-72.
10. Filaci G, et al. Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and
interleucin-6 serum changes after 12 months of therapy. Rheumatology (Oxford) 1999;38:992-6.
11 Clements PJ, Furst DE. Choosing appropriate patients with systemic sclerosis for treatment autologous
stem cell transplantation. J Rheumatol 1997;48:85-8
12. Lin AT, et al. Update on disease-modifying antirheumatic drugs in the treatment og systemic
sclerosis. Rheum Dis Clin N Am 2003;29:409-426
13. Akesson A., et al. Improved pulmonary function in systemic sclerosis after treatment with
cyclophosphamide. Arthritis Rheum 1996;39:1132-7
14. Davas EM, et al. Intravenous cyclophosphamide pulse therapy for treatment of lung disease
associated with scleroderma. Clin Rheumatol 1999;18:455-61.
15. Badasch DB, et al. Continous intravenous epoprostenol for pulmonary hypertension due to the
scleroderma spectrum disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-434.
16. Simonneau G, et al. Continous subcutaneous infusion of treprostinil, a prostacyclin analogue, in the
patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am
Respir Crit Care Med 2002;165:800-4.
17. Channick RN, et al. Bosentan, a dual endothelin receptor antagonist,improves exercise capacity and
haemodynamics in patients with pulmonary arterial hypertension: a randomized placebo-controlled study.
Lancet 2001;358:1119-23.
18. Rubin LJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-
903
19. Lopez-Ovejero JA, et al. Reversal of vascular and renal crisis of scleroderma by oral angiotensin
converting enzyme blockade. N Engl J Med 1979;300:1417-9.
20. Steen VD., et al. Outcome of renal crisis in systemic sclerosis: relation to avaibility of angiotensin
converting enzyme inhibitors. Ann Intern Med 1990;113:352-7.
21. Stten VD., et al. Case-control study of cortocosteroids and other drug that either precipitate or protect
from the development of scleroderma renal crisis. Arthritis Rheum 1998;41:1613-9.
22. Sjogren RW, et al. Gastrointestinal features of scleroderma. Curr Opin Rheumatol 1996;8:569-75.